BioTech IP Review

Patent Title: Compositions of Thymic Stromal Lymphopoietin (TSLP) Binding Fragments and Methods of Use Thereof
Publication Number: WO/2025/163008
Application Number: PCT/EP2025/052281
Filing Date: January 29, 2025
Publication Date: August 07, 2025
Applicant / Assignee: AstraZeneca AB (Sweden)

---

What This Patent Covers

This international patent application focuses on antibody‑based compositions that bind Thymic Stromal Lymphopoietin (TSLP) — a key cytokine involved in initiating and amplifying type 2 inflammatory responses in diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and other allergic or immune‑mediated conditions.

Key aspects of the invention include:

• TSLP‑binding fragments: The core invention claims specific antibody fragments or related binding molecules that recognize and bind TSLP with high affinity. These are engineered to neutralize TSLP activity.
• Pharmaceutical compositions: The patent describes formulations that incorporate these TSLP binders for therapeutic use.
• Methods of use: It also covers methods of treating or preventing inflammatory diseases by administering the TSLP binding compositions (e.g., via injection or other routes), thus blocking TSLP‑mediated signaling in patients.

TSLP is a well‑validated target in asthma and related diseases because it acts upstream in the inflammatory cascade, and blocking it can reduce downstream effects from multiple immune pathways. (Note: Tezepelumab — a TSLP‑targeting antibody — has already proven the clinical value of this mechanism, showing that further optimized TSLP‑binding agents could capture substantial market share.)

---

Why This Patent Is Important

1) Aligns with high‑growth therapeutic areas:
Asthma, allergic diseases, and type 2 inflammation represent multi‑billion‑dollar markets worldwide. Drugs targeting TSLP (like tezepelumab) have demonstrated significant clinical benefits, validating TSLP as a high‑value target. This patent extends AstraZeneca’s IP in a hot therapeutic class.

2) Platform and differentiation potential:
Compositions and use methods covering TSLP binders could support next‑generation biologics — potentially with improved efficacy, safety, or dosing advantages versus existing therapies.

3) Strategic IP position:
Owning broad patents on TSLP binding fragments and their therapeutic use helps AstraZeneca defend its position in immunology and compete with other biologics developers targeting upstream cytokines in inflammatory pathways.